Chondroitin Market size is expected to witness appreciable growth over 2021-2027. This is driven by the rising intake of this dietary supplement to prevent cartilage breakdown and stimulate its repair mechanisms. Furthermore, the emergence of chondroitin sulfate as a potential compound to relieve arthritis pain due to its anti-inflammatory properties will further proliferate industry growth in the years ahead.
Chondroitin refers to a molecule that naturally occurs in the body and provides a building block to produce new cartilage in the body. Commercial chondroitin is usually derived from natural sources, including bovine and shark cartilage, or through synthetic production.
Rising prevalence of osteoarthritis among the elderly population and the subsequent increase in chondroitin clinical studies are the key trends bolstering the chondroitin market growth over 2021-2027. The expanding osteoarthritis patient base will contribute to the rising product demand, as chondroitin can help keep the cartilage healthy by absorbing the fluid, particularly water, into the connective tissue. Moreover, the increasing burden of cataracts will also drive the market share, given the usage of chondroitin sulfate emulsion to effectively reduce the symptoms of dry eye disease.
On the basis of end-use, the chondroitin market from the cardiovascular health segment will witness a major upsurge by 2027. This is driven by the capability of chondroitin and glucosamine supplements to reduce the risks of stroke, coronary heart disease, and CVD-related deaths. According to the CDC, more than 795,000 people have a stroke every year in the U.S. This rising burden of cardiovascular ailments on the global population will generate opportunities for chondroitin brands to grow exponentially over the forecast spell.
From a regional perspective, the Latin America chondroitin industry will depict a strong growth rate through 2027. This is a result of the rising incidences of rheumatic disorders, including arthritis, in countries such as Brazil. Additionally, the high prevalence of obesity and other chronic disorders among Latin American adults will stimulate the regional industry dynamics in the upcoming years. According to a National Center For Biotechnology Information report, chronic diseases claim the lives of over 928,000 people per year in Brazil. Factors such as these could, in turn, amplify demand for supplements like chondroitin and glucosamine over the years ahead.
The competitive landscape of the global chondroitin market consists of companies such as Nippon Zoki, Synutra International, Sioux Pharm, TSI Group, and Pacific Rainbow, among others. Strategic mergers and acquisitions, business expansions, and innovative product launches are among the key initiatives being undertaken by these industry players to gain a competitive edge over other rivals in the global market. For instance, in May 2021, Bioiberica partnered with Apsen to launch a new mobility product in Brazil, dubbed Motilex HA. The produce features features Bioiberica’s Mobilee and b-2Cool ingredients, alongside other key joint health ingredients like chondroitin sulphate.
The ongoing coronavirus pandemic has impacted the healthcare industry significantly over the past year, disrupting treatment access for patients with non-communicable chronic diseases worldwide. According to a study from the BMC Public Health journal in April 2021, people with chronic conditions such as hypertension and diabetes, especially among rural and marginalized populations, witnessed difficulties in accessing healthcare services, due to social and financial constraints. Factors such likely created a hindrance to the consumption of chondroitin, as it is often used to reduce the symptoms of chronic conditions like cancer.
However, the emergence of AVN (Avascular Necrosis), also referred to as bone death, as one of the major post-COVID complications may aid the chondroitin industry recovery over the coming years. This type of bone disease or painful condition affecting the thigh bones and hip joint has become prominent among the coronavirus recovered patients and could take years for recovery. Such situations may augment the adoption of chondroitin, given its ability to reduce the weakening of bones and support healthy growth.